ANGN's logo.
Ticker Symbol: ANGN

Angion Biomedica Corp

$4.23 - 14-07-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001601485

Company Profile

Angion Biomedica Corp. is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluating in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation, a Phase 2 trial in cardiac-surgery associated acute kidney injury, and a Phase 2 trial in patients with COVID-19 related pneumonia at high risk for acute respiratory distress syndrome. Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags: N/A

Pricing

Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: - ( 0.00%)
Days Range: $0.89 - $100.00
Beta: 0.91
52wk. High: $2.04
52wk. Low: $0.46
Ytd. Change 23.21%
50 Day Moving Average: $0.78
200 Day Moving Average: $0.73
Shares Outstanding: 30113703

Valuation

Market Cap: 301.1B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A